ArticlePediatric nephrology (Berlin, Germany)2026
Suppressor of cytokine signaling 2 is associated with growth impairment in pediatric chronic kidney disease.
Article in Pediatric nephrology (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Growth and development following paediatric kidney transplantation: Mechanisms, influencing factors, and clinical management.World journal of transplantation · 2026Review
- Linear growth in pediatric kidney transplant recipients.Pediatric nephrology (Berlin, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGrowth failure is a common and serious complication of chronic kidney disease (CKD) in children, resulting from numerous factors, including growth hormone (GH) resistance. Suppressor of cytokine signaling 2 (SOCS2), a negative regulator of GH signaling, has been implicated in growth regulation but has not been previously studied in pediatric CKD.
methodsIn this cross-sectional study, we assessed serum SOCS2 concentrations in 55 children with CKD (stages 2-5) and 27 age- and sex-matched healthy controls using a high-sensitivity ELISA. We evaluated anthropometric parameters, kidney function, and biochemical markers. Associations between SOCS2 levels and growth (height standard deviation scores, HtSDS) were analyzed using correlation and multivariate regression models.
resultsSOCS2 levels were significantly higher in children with CKD compared to controls (median 1526.5 vs. 1294.6 pg/ml, p < 0.001). In patients with CKD, SOCS2 negatively correlated with HtSDS (r = -0.30, p = 0.029). In multivariate analysis, SOCS2 was an independent predictor of lower HtSDS alongside eGFR. SOCS2 concentrations were higher in short-statured children, and ROC analysis showed acceptable diagnostic performance for predicting short stature (AUC 0.78, 95% CI 0.64-0.91; 79.5% sensitivity, 68.8% specificity).
conclusionsCirculating SOCS2 levels are elevated in pediatric CKD and independently associated with growth impairment, suggesting its potential link to GH resistance, which is typical of CKD. SOCS2 might be a potential new marker of growth retardation. Further longitudinal studies are needed to explore its predictive value for longitudinal growth and GH treatment response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.